Início › Leucemia Mieloide Aguda › Arkansas › Little Rock
Ensaios clínicos de Leucemia Mieloide Aguda em Little Rock, AR
13 estudos para Leucemia Mieloide Aguda estão buscando participantes em locais em Little Rock e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecrutandoFase 2
- University of Arkansas for Medical Sciences, Little Rock
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
- CARTI Cancer Center, Little Rock
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
RecrutandoFase 2
- University of Arkansas for Medical Sciences, Little Rock
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
RecrutandoFase 3
- University of Arkansas at Little Rock, Little Rock
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
RecrutandoFase 2
- University of Arkansas for Medical Sciences, Little Rock
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RecrutandoFase 2
- University of Arkansas for Medical Sciences, Little Rock
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RecrutandoFase 2
- University of Arkansas for Medical Sciences, Little Rock
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RecrutandoFase 3
- Arkansas Children's Hospital, Little Rock
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
RecrutandoFase 3
- Arkansas Children's Hospital, Little Rock
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecrutandoFase 1/2
- Arkansas Children's Hospital, Little Rock
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
RecrutandoFase 3
- Arkansas Children's Hospital, Little Rock
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecrutandoEstudo observacional
- Arkansas Children's Hospital, Little Rock
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
RecrutandoFase 1
- Arkansas Children's Hospital, Little Rock
Ensaios de Leucemia Mieloide Aguda em outras cidades
- Houston, TX85 estudos
- New York City, NY51 estudos
- Boston, MA44 estudos
- Seattle, WA41 estudos
- Baldwin Park, CA40 estudos
- Columbus, OH35 estudos
- Philadelphia, PA34 estudos
- Durham, NC33 estudos
- Atlanta, GA31 estudos
- Tampa, FL29 estudos
- Chicago, IL26 estudos
- Portland, OR25 estudos
Outros estudos em Little Rock
- Esquizofrenia19 estudos
- Câncer (todos os tipos)14 estudos
- Transtorno Depressivo Maior14 estudos
- Câncer de Pulmão de Não Pequenas Células13 estudos
- Obesidade11 estudos
- Câncer Endometrial10 estudos
- Depressão10 estudos
- Diabetes tipo 210 estudos
- Câncer de Pulmão9 estudos
- Doença Cardiovascular9 estudos
- Câncer de Bexiga9 estudos
- Insuficiência Cardíaca9 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.